Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ardelyx Inc
ARDX | US
5.61
USD0.07
1.26%
ARDX | US
Loading StockChartView...
About Ardelyx Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/06/2026
Close
5.61
Open
5.55
High
5.91
Low
5.54
Ardelyx Inc. a biopharmaceutical company discovers develops and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis or hyperphosphatemia; RDX013 a potassium secretagogue for the treatment of elevated serum potassium or hyperkalemia a problem among certain patients with kidney and/or heart disease; and RDX020 for adult patients with metabolic acidosis a serious electrolyte disorder. The company has agreements with Kyowa Kirin Fosun Pharmaceutical Industrial Development Co. Ltd. and Knight Therapeutics Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx Inc. and changed its name to Ardelyx Inc. in June 2008. Ardelyx Inc. was incorporated in 2007 and is headquartered in Waltham Massachusetts.
View LessARDX | US
Risk
38.7
Sharpe
0.77
Luna's Score
45/100
Recommendation
Sell
Luna says (ARDX | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
40.1%1 month
38.7%3 months
47.2%6 months
67.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
9.34
Debt to equity
0.71
Debt to assets
0.31
Ent. to EBITDA
-27.36
Ent. to rev.
6.15
PEG
-0.08
Other Fundamentals
EBITDA
-57.24M
MarketCap
1.32B
MarketCap(USD)
1.32B
Div. yield
-
Op. margin
-18.62
Erngs. growth
-
Rev. growth
227.90
Ret. on equity
-48.23
Short ratio
8.00
Short perc.
11.14
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.04
Range1M
1.52
Range3M
2.33
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.95
Price X volume
16.34M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -27.36 | 0.53 | Cheaper |
| Ent. to Revenue | 6.15 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 9.34 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 47.17 | 72.80 | Lower Risk |
| Debt to Equity | 0.71 | -1.23 | Expensive |
| Debt to Assets | 0.31 | 0.25 | Expensive |
| Market Cap | 1.32B | 3.66B | Emerging |
